Reported paediatric adverse drug reactions in the UK 2000-2009

British Journal of Clinical Pharmacology

Volumn 73, Issue 3, 2012, Pages 437-446

  Hawcutt, Daniel B ^a   Mainie, Pramod ^b   Riordan, Andrew ^c   Smyth, Rosalind L ^a   Pirmohamed, Munir ^a  

^a UNIVERSITY OF LIVERPOOL   (United Kingdom)

^b NORTHWICK PARK HOSPITAL   (United Kingdom)

^c ALDER HEY CHILDREN S HOSPITAL   (United Kingdom)

Author keywords

Adverse drug reaction; Paediatrics; Pharmacology

Indexed keywords

ANESTHETIC AGENT; ANTIARRHYTHMIC AGENT; ANTIBIOTIC AGENT; ANTIFUNGAL AGENT; ANTIHYPERTENSIVE AGENT; ANTIVIRUS AGENT; ATOMOXETINE; BCG VACCINE; BENZODIAZEPINE DERIVATIVE; CARBAMAZEPINE; CHELATING AGENT; ETANERCEPT; FLUTICASONE PROPIONATE PLUS SALMETEROL; LAMOTRIGINE; MENINGOCOCCUS SEROGROUP C CONJUGATE VACCINE; MENINGOCOCCUS VACCINE; METHYLPHENIDATE; MONTELUKAST; PARACETAMOL; PNEUMOCOCCUS VACCINE; POLIOMYELITIS VACCINE; RISPERIDONE; TOPIRAMATE; UNCLASSIFIED DRUG; VALPROIC ACID; WART VIRUS VACCINE;

ADVERSE DRUG REACTION; AGGRESSION; ARTICLE; BCG VACCINATION; CONVULSION; DIZZINESS; DRUG INDUCED HEADACHE; ERYTHEMA; FEVER; HAEMOPHILUS INFLUENZAE; HEALTH CARE PERSONNEL; HEALTH CARE POLICY; HUMAN; MALAISE; MENINGOCOCCOSIS; NAUSEA; PAPILLOMAVIRUS INFECTION; PERIPHERAL EDEMA; PERTUSSIS; PHARMACIST; POLIOMYELITIS; PRIORITY JOURNAL; PRURITUS; SIDE EFFECT; SYNCOPE; UNITED KINGDOM; URTICARIA; VACCINATION; VOMITING;

ADOLESCENT; ADVERSE DRUG REACTION REPORTING SYSTEMS; CHILD; CHILD, PRESCHOOL; DRUG TOXICITY; GREAT BRITAIN; HEALTH PERSONNEL; HUMANS; INFANT; PHARMACEUTICAL PREPARATIONS; VACCINATION;

EID: 84856999688     PISSN: 03065251     EISSN: 13652125     Source Type: Journal    
DOI: 10.1111/j.1365-2125.2011.04113.x     Document Type: Article

References (39)

1. Office for National Statistics. Key Population and Vital Statistics. Key Population and Vital Statistics No 34, PPI No 30, 2007 Data: population and vital statistics by area of usual residence in the United Kingdom, 2007. 2009. Available at (last accessed 31 October 2011).
2. Office for National Statistics. Prescriptions dispensed in the community statistics for 1997 to 2007: England. 2008. Available at (last accessed 17 May 2011).
3. Shirkey H. Editorial comment: therapeutic orphans. J Pediatr 1968; 72: 119-20.
4. Stephenson T. The medicines for children agenda in the UK. Br J Clin Pharmacol 2006; 61: 716-9.
5. Turner S, Nunn AJ, Fielding K, Choonara I. Adverse drug reactions to unlicensed and off-label drugs on paediatric wards: a prospective study. Acta Paediatr 1999; 88: 965-8.
6. Choonara I, Conroy S. Unlicensed and off-label drug use in children - implications for safety. Drug Saf 2002; 25: 1-5.
7. Hawcutt DB, Smyth RL. The new European regulation on pediatric medicines: regulatory perspective. Pediatr Drugs 2008; 10: 143-6.
8. Horen B, Montastruc JL, Lapeyre-Mestre M. Adverse drug reactions and off-label drug use in paediatric outpatients. Br J Clin Pharmacol 2002; 54: 665-70.
9. Smyth RMD, Gargon E, Kirkham JJ, Cresswell L, Smyth RL, Williamson PR. Adverse drug reactions in children - a systematic review. PLoS Med 2011 (in press). Available at (last accessed 31 October 2011).
10. Mittmann N, Knowles SR, Gomez M, Fish JS, Cartotto R, Shear NH. Evaluation of the extent of under-reporting of serious adverse drug reactions - the case of toxic epidermal necrolysis. Drug Saf 2004; 27: 477-87.
11. Fletcher AP. Spontaneous adverse drug reaction reporting vs. event monitoring - a comparion. J R Soc Med 1991; 84: 341-4.
12. Morrison-Griffiths S, Walley TJ, Park BK, Breckenridge AM, Pirmohamed M. Reporting of adverse drug reactions by nurses. Lancet 2003; 361: 1347-8.
13. Egberts TCG, Smulders M, deKoning FHP, Meyboom RHB, Leufkens HGM. Can adverse drug reactions be detected earlier? A comparison of reports by patients and professionals. BMJ 1996; 313: 530-1.
14. McLernon DJ, Bond CM, Hannaford PC, Watson MC, Lee AJ, Hazell L, Avery A. Adverse drug reaction reporting in the UK: a retrospective observational comparison of yellow card reports submitted by patients and healthcare professionals. Drug Saf 2010; 33: 775-88.
15. Silvers LE, Varricchio FE, Ellenberg SS, Krueger CL, Wise RP, Salive ME. Pediatric deaths reported after vaccination - the utility of information obtained from parents. Am J Prev Med 2002; 22: 170-6.
16. Department of Health. The Meningitis C Campaign. London: Department of Health, 2009. Available at (last accessed 17 May 2011).
17. Trotter CL, Edmunds WJ. Modelling cost effectiveness of meningococcal serogroup C conjugate vaccination campaign in England and Wales. Br Med J 2002; 324: 809.
18. Miller E, Salisbury D, Ramsay M. Planning, registration, and implementation of an immunisation campaign against meningococcal serogroup C disease in the UK: a success story. Vaccine 2001; 20: (Suppl. 1): S58-67.
19. Donaldson L, Mullally S, Smith J. Current vaccine and immunisation issues. Department of Health; 2001. Available at (last accessed 31 October 2011).
20. Committee on the Safety of Medicines, part of the MHRA. SSI BCG vaccine and local reactions. Current Problems in Pharmacovigilance 2004. p. 8.
21. Donaldson L, Mullally S, Smith J. New vaccinations for the childhood immunisation programme. Department of Health; 2004. Available at (last accessed 17 May 2011).
22. Donaldson L, Beasley C, Smith J. Changes to the BCG vaccination programme. Department of Health; 2005. Available at (last accessed 17 May 2011).
23. Donaldson L, Beasley C, Ridge K. Important changes to the childhood immunisation programme. Department of Health; 2006. Available at (last accessed 17 May 2011).
24. Donaldson L, Beasley C, Ridge K. Introduction of Human Papilloma virus vaccination into the national immunisation programme. Department of Health; 2008. Available at (last accessed 17 May 2011).
25. Bates G. Drug treatments for attention-deficit hyperactivity disorder in young people. Adv Psychiatr Treat 2009; 15: 162-71. Available at (last accessed 31 October 2011).
26. Strom BL. Pharmacoepidemiology. 2nd edn. Chichester, UK: J. Wiley, 2005.
27. Belton KJ. Attitude survey of adverse drug-reaction reporting by health care professionals across the European Union. Eur J Clin Pharmacol 1997; 52: 423-7.
28. Crombie I. Inherent limitations of the yellow card system for the detection of unsuspected adverse drug reactions. Hum Exp Toxicol 1984; 3: 261-9.
29. Clarkson A, Choonara I. Surveillance for fatal suspected adverse drug reactions in the UK. Arch Dis Child 2002; 87: 462-6.
30. Sacristán JA, Gómez JC, Badía X, Kind P. Global index of safety (GIS): a new instrument to assess drug safety. J Clin Epidemiol 2001; 54: 1120-5. [doi: DOI: 10.1016/S0895-4356(01)00384-5].
31. Rawlins MD. Pharmacovigilance - paradise-lost, regained or postponed - the William Withering lecture 1994. J R Coll Physicians Lond 1995; 29: 41-9.
32. Committee on the Safety of Medicines, part of the MHRA. Current Problems in Pharmacovigilance 1998.
33. Committee on the Safety of Medicines, part of the MHRA. Safety of meningococcal group C conjugate vaccines. Current Problems in Pharmacovigilance: Medicines Control Agency/Committee on Safety of Medicines. 2000. p. 14.
34. Impicciatore P, Choonara I, Clarkson A, Provasi D, Pandolfini C, Bonati M. Incidence of adverse drug reactions in paediatric in/out-patients: a systematic review and meta-analysis of prospective studies. Br J Clin Pharmacol 2001; 52: 77-83.
35. Yergeau A, Alain L, Pless R, Robert Y. Adverse events temporally associated with meningococcal vaccines. Can Med Assoc J 1996; 154: 503-7.
36. Teo SS, Smeulders N, Shingadia DV. BCG vaccine-associated suppurative lymphadenitis. Vaccine 2005; 23: 2676-9.
37. Purssell E. Uncertainties and anxieties about vaccination, answering parent's concerns. J Pediatr Nurs 2009; 24: 433-40.
38. Deer B. How the case against the MMR vaccine was fixed. BMJ 2011; 342: c5347.
39. Prescott LF. Therapeutic misadventure with paracetamol: fact or fiction? Am J Ther 2000; 7: 99-114.